Protalix is a biopharmaceutical company focused on the development, production, and commercialization of innovative medicines for patients living with rare diseases. We are advancing promising candidates leveraging our expertise in protein therapeutics through our proprietary, commercial-scale ProCellEx® plant cell-based protein expression system, as well as our chemical and genetic modification capabilities, including PEGylation. With two approved drugs already making an impact, we are committed to expanding our pipeline to address the unmet needs of patients facing some of the most challenging rare diseases.

Stock Quote

Protalix Biotherapeutics ( American: )

Data Provided by Refinitiv. Minimum 15 minutes delayed.